On 21 March 2012, orphan designation (EU/3/12/973) was granted by the European Commission to NDA Regulatory Science Ltd, United Kingdom, for recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type VII (Sly syndrome).
"Jetfuel Superburn" is being recalled after Health Canada tests confirmed it contains two undeclared amphetamine-like drug substances that pose serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of Terrebonne, Quebec, is recalling the product from retail stores across Canada. Jetfuel Superburn is promoted for body building purposes, including for weight loss and increased energy.
The September issue of Danish Pharmacovigilance Update.
News from the EU
Denosumab (Prolia and Xgeva) and risk of osteonecrosis of the jaw and hypocalcaemia, page 2
Interferon beta and risk of serious adverse reactions, page 4
News from the DHMA
Scopoderm® transdermal patches and visual disturbances, page 5
Childhood vaccinations and reported suspected adverse reactions in Q2 of 2014, page 6
Most recent Direct Healthcare Professional Communications (DHPCs), page 13